JW Pharmaceutical Corp (001067) — Cash Flow Quality Index

Latest as of September 2025: 1.53x

JW Pharmaceutical Corp (001067) has a Cash Flow Quality Index of 1.53x as of September 2025. Operating cash flow of ₩46.92 Billion exceeds net income of ₩30.59 Billion, indicating high earnings quality where cash backs reported profits. Explore JW Pharmaceutical Corp cash flow conversion to assess how effectively this company generates cash.

Cash Flow Quality Index

1.53x
Operating CF / Net Income

Operating Cash Flow

₩46.92 Billion
KRW

Net Income

₩30.59 Billion
KRW

Data as of

Sep 2025
Most recent filing

JW Pharmaceutical Corp Cash Flow Quality Index (2015–2024)

Historical Cash Flow Quality Index for JW Pharmaceutical Corp across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 001067 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for JW Pharmaceutical Corp (2015–2024)

Year-by-year earnings quality comparison for JW Pharmaceutical Corp. For live market cap and the full company financial profile, see JW Pharmaceutical Corp market capitalisation.

Year Quality Index Operating CF (KRW) Net Income YoY Change
2024 1.22x ₩79.39 Billion ₩65.04 Billion ▼ -51.2%
2023 2.50x ₩87.16 Billion ₩34.84 Billion ▲ +47.8%
2022 1.69x ₩56.76 Billion ₩33.55 Billion ▼ -73.8%
2018 6.47x ₩52.11 Billion ₩8.06 Billion ▲ +403.9%
2015 -2.13x ₩-4.17 Billion ₩1.96 Billion
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.